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Fig. 1. Aprotinin plasma concentrations. The left part of the figure shows aprotinin concentrations (mean + 
standard eviation) in plasma samples directly drawn from the patient and in specimens that were rotated for 
10 minutes in either celite or kaolin test tubes. The right side shows the individual measurements for each 
patient. Aprotinin was almost undetectable in the kaolin tubes, which indicates abinding of aprotinin to kaolin. 
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Use of an intraluminal shunt to repair a coronary 
bypass graft injury during resternotomy 
T. Carrel, MD, M. Pasic, MD, U. Niederhfiuser, 
MD, and M. Turina, MD, Zurich, Switzerland 
In recent years, there has been an increase in the 
number of patients who are subjected to second cardiac 
procedures for correction of congenital heart defects, 
valve problems, and repeat coronary artery revasculariza- 
tion. Catastrophic hemorrhage is a rare complication that 
may occur while the sternum is being reopened. The most 
frequent causes include tears of the right ventricle and 
lesions of previous coronary bypass grafts; less common 
are bleeding from ascending aortic aneurysms or tears in 
the right atrium. 
In 1985, a 66-year old patient had undergone an aortic 
valve replacement with a Capentier-Edwards bioprosthe- 
sis (Baxter Healthcare Corp., Edwards Div., Santa Aria, 
Calif.) and a saphenous vein graft to the circumflex artery 
with jump anastomoses to an intermediate branch, the 
first diagonal branch, and the left anterior descending 
artery. Postoperative r covery was uneventful, and the 
patient felt well until 1992. At this time, the patient 
reported having exertional dyspnea nd increasing weari- 
ness. A cardiologic examination was performed and trans- 
thoracic echocardiography demonstrated degeneration f
the bioprosthesis, resulting in moderate aortic stenosis 
(mean systolic gradient 45 mm Hg, peak-to-peak gradient 
70 mm Hg, and a valve opening area of 0.8 cm2). I~ft 
ventricular function was severely depressed with an ejec- 
tion fraction of 0.26. At coronary angiography, each 
coronary-saphenous vein anastomosis was patent but 
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Fig. 1. Insertion of a silicone stent, secured with tourni- 
quets, between the vein graft segments. 
Fig. 2. A short vein graft was used to repair the lesion 
and exclude the aneurysmal segment. 
some atherosclerotic changes were described in the prox- 
imal part of the graft. 
A median sternotomy was performed with the oscillat- 
ing saw; during preparation and mobilization of the 
sternal borders, the aneurysmal proximal part of the 
saphenous vein bypass graft, which was completely adher- 
ent to the sternum, was damaged. Because of the impor- 
tant myocardial area supplied by the graft, it could not 
have been occluded either with clamps or with Fogarty 
catheters. Therefore we elected to insert a small intralu- 
minal silicone shunt, which is usually used during carotid 
endarterectomy to preserve homolateral cerebral perfu- 
sion, as a bridge between the proximal and distal vein graft 
segments and secured it with tourniquets (Fig. 1). With 
this technical assistance, the bleeding could be easily 
controlled and no electrocardiographic changes or hemo- 
dynamic alterations appeared. 
Femoral artery cannulation was then performed, the 
right atrium was dissected, and a single-stage cannula was 
introduced into the right atrium. Extracorporeal circula- 
tion was instituted and conducted at moderate hypother- 
mia. Myocardial protection was performed by retrograde 
continuous cardioplegia. After the aorta was cross- 
clamped, the bioprosthesis was resected and a mechanical 
prosthesis was inserted. A short venous graft was inter- 
posed to repair the lesion and exclude the aneurysmal 
segment (Fig. 2). Postoperative r covery was uneventful 
and no clinical or electrocardiographic signs of periopera- 
tive myocardial infarction appeared. The patient was 
discharged on postoperative day 10. 
Several factors account for the increased risk of reop- 
eration: age, progressive xtent of coronary atherosclero- 
sis, impairment of left ventricular function, additional 
cardiac procedures, technical difficulties during reentry 
and caused by intrapericardial dhesions, and prolonged 
bypass time and more difficult myocardial protection. 1 
Various methods have been proposed in the past for 
sternal reentry. Femoral artery cannulation can be used 
when the right ventricle seems to be adherent o the 
sternum, when there is strong suspicion that the internal 
mammary artery or a venous bypass graft is crossing the 
midline, when the chest has been reconstructed bymuscle 
flaps, and when an ascending aortic aneurysm is 
present.a, 3 
When progressive coronary artery disease necessitates a 
second operation with a new graft to the anterior and 
posterolateral walls of the left ventricle, thoractomy may 
allow excellent exposure of the left anterior descending 
branch and obtuse marginal branches. Proximal anasto- 
moses are then performed to the descending aorta. 4
In the case presented here, the use of an intraluminal 
shunt allowed us to control the bleeding and maintain a 
sufficient perfusion to prevent myocardial ischemia; fur- 
thermore, it allowed controlled, unhurried institution of 
cardiopulmonary b pass. This elegant method, preventing 
bleeding and myocardial ischemia, prompted us to review 
the literature, and we found only one similar description. 5 
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